Skip to main content

Table 1 Patient characteristics

From: Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ

  all pts. (n = 131) DCIS pts. (n = 96) miCa pts. (n = 35) p value(*)
mean age [range] 56 [36–84] 56 [36–84] 54 [38–78] NS
initial management     
 lumpectomy 89 (68%) 68 (71%) 21 (60%) NS
 mastectomy 42 (32%) 28 (29%) 14 (40%)  
adjuvant treatment     
 radiotherapy 89 (68%) 68 (71%) 21 (60%) NS
 endocrine treatment 10 (8%) 1 (1.0%) 9 (26%) <  0.0001
 cytotoxic treatment 2 (2%) 0 (0.0%) 2 (6%) 0.03
 observation 39 (30%) 27 (28%) 12 (34%) NS
 trastuzumab 1 (1%) 0 (0%) 1 (3%) NS
 recurrences 18 (14%) 14 (14%) 4 (11%) NS
 DFS at 5 years 94% (n = 124) 94% (n = 91) 94% (n = 34) NS
 DFS at 10 years 89% (n = 108) 88% (n = 78) 91% (n = 31)
  1. Abbreviations: DCIS pure DCIS, miCa microinvasive carcinoma, DFS disease-free survival, NS not significant, (*) characterizing the difference between DCIS and miCa